Preclinical evaluation of the anti-tumor activity of pralatrexate in high-risk neuroblastoma cells

Introduction: Pralatrexate is a folate analogue inhibitor of dihydrofolate reductase exhibiting high affinity for reduced folate carrier-1 with antineoplastic and immunosuppressive activities, similar to methotrexate. Despite advances in multi-modality treatment strategies, the survival rates for ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Clark, Rachael A., Lee, Sora, Qiao, Jingbo, Chung, Dai H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429182/
https://www.ncbi.nlm.nih.gov/pubmed/32850011
http://dx.doi.org/10.18632/oncotarget.27697

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429182/
https://www.ncbi.nlm.nih.gov/pubmed/32850011
http://dx.doi.org/10.18632/oncotarget.27697

Ejemplares similares